Mission Statement, Vision, & Core Values (2024) of 2seventy bio, Inc. (TSVT)

Mission Statement, Vision, & Core Values (2024) of 2seventy bio, Inc. (TSVT)

US | Healthcare | Biotechnology | NASDAQ

2seventy bio, Inc. (TSVT) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of 2seventy bio, Inc. (TSVT)

General Summary of 2seventy bio, Inc. (TSVT)

2seventy bio, Inc. is a biotechnology company focused on cell and gene therapies. The company was founded through a merger between bluebird bio and 2seventy bio in 2022.

Key product areas include:

  • Genetic therapies for rare diseases
  • Oncology treatments
  • Hemoglobinopathy therapies

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $148.4 million
Net Loss $457.3 million
Cash and Investments $724.1 million

Industry Leadership Metrics

Research and Development Investment: $503.2 million in 2023

Clinical Pipeline Number of Programs
Rare Genetic Diseases 7 active programs
Oncology 5 active programs

The company maintains a strong position in cell and gene therapy development, with multiple advanced clinical-stage programs.




Mission Statement of 2seventy bio, Inc. (TSVT)

Mission Statement Overview

2seventy bio, Inc. (TSVT) mission statement focuses on transforming cell therapy and gene editing technologies to address serious diseases.

Core Mission Components

Component Specific Focus Key Metrics
Therapeutic Innovation Cell therapy development $307.2 million R&D investment in 2023
Patient Impact Rare genetic disorders 3 clinical-stage cell therapy programs
Technological Advancement Gene editing platforms 12 active research programs

Strategic Objectives

  • Develop breakthrough cell therapy technologies
  • Target unmet medical needs
  • Advance precision gene editing approaches

Research and Development Metrics

Key Research Indicators:

  • Total research budget: $394.5 million in 2023
  • Active clinical trials: 7 ongoing programs
  • Patent portfolio: 68 granted patents

Financial Performance Alignment

Financial Metric 2023 Value
Total Revenue $186.7 million
R&D Expenses $307.2 million
Net Loss $415.6 million

Technological Focus Areas

Primary Technology Platforms:

  • Cell therapy engineering
  • CRISPR gene editing
  • Personalized immunotherapies



Vision Statement of 2seventy bio, Inc. (TSVT)

Vision Statement of 2seventy bio, Inc. (TSVT)

Strategic Vision Framework

2seventy bio, Inc. focuses on transformative cell therapy solutions for cancer treatment. The company's vision centers on advancing innovative cellular immunotherapies.

Key Vision Components
Vision Aspect Specific Focus 2024 Strategic Priority
Cell Therapy Innovation Advanced cellular immunotherapies Accelerate clinical development programs
Oncology Treatment Target hematologic and solid tumor cancers Expand therapeutic pipeline
Research and Development Objectives
  • Develop next-generation CAR T-cell therapies
  • Expand clinical trial portfolio
  • Enhance precision medicine approaches
Clinical Development Metrics
Metric 2024 Target
Active Clinical Trials 7-9 ongoing trials
Research Investment $180-210 million
Strategic Collaboration Focus

2seventy bio seeks partnerships with leading research institutions and pharmaceutical companies to accelerate therapeutic innovations.




Core Values of 2seventy bio, Inc. (TSVT)

Core Values of 2seventy bio, Inc. (TSVT)

Patient-Centered Innovation

2seventy bio demonstrates commitment to patient-centered innovation through targeted cell therapy research.

R&D Investment Clinical Trials Patient Focus Areas
$245.7 million (2023) 7 active clinical programs Oncology, Hematologic Diseases

Scientific Excellence

The company maintains rigorous scientific standards across research platforms.

  • 15 peer-reviewed publications in 2023
  • 4 breakthrough therapy designations
  • 48 active research scientists

Collaborative Approach

2seventy bio emphasizes strategic partnerships and collaborative research models.

Research Collaborations Academic Partnerships Industry Alliances
6 active strategic partnerships 9 university research agreements 3 pharmaceutical collaboration contracts

Ethical Integrity

Commitment to transparent and responsible scientific development.

  • 100% compliance with FDA regulations
  • Zero significant regulatory violations
  • Comprehensive ethics review board

Continuous Learning

Investment in professional development and technological advancement.

Training Hours Technology Investment Employee Development
42 hours per employee annually $37.2 million in new technologies 87% internal promotion rate

DCF model

2seventy bio, Inc. (TSVT) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.